Accessibility Menu
MoonLake Immunotherapeutics Stock Quote

MoonLake Immunotherapeutics (NASDAQ: MLTX)

$9.42
(-1.9%)
-0.18
Price as of October 23, 2025, 2:50 p.m. ET

KEY DATA POINTS

Current Price
$9.4
Daily Change
(-1.9%) $0.18
Day's Range
$9.31 - $9.67
Previous Close
$9.6
Open
$9.61
Beta
0.49
Volume
1,128,236
Average Volume
4,181,055
Market Cap
609.6M
Market Cap / Employee
$9.60M
52wk Range
$5.95 - $62.75
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.79
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

MoonLake Immunotherapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MLTX-80%-9.09%-1.89%-8%
S&P+14.5%+93.32%+14.09%+95%

MoonLake Immunotherapeutics Company Info

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.74M-2539.4%
Market Cap$3.00B8.4%
Market Cap / Employee$29.96M0.0%
Employees100100.0%
Net Income-$56.05M-126.4%
EBITDA-$59.96M-96.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$306.68M-10.5%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$74.22M3570.0%
Short Term Debt$1.55M17.3%

Ratios

Q2 2025YOY Change
Return On Assets-35.06%-24.6%
Return On Invested Capital64.98%-22.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$54.53M-95.5%
Operating Free Cash Flow-$54.53M-95.5%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book6.096.995.527.3544.28%
Price to Tangible Book Value6.096.995.527.3544.28%
Enterprise Value to EBITDA-62.40-61.65-43.97-44.06-40.37%
Return on Equity-17.7%-25.2%-30.6%-40.3%271.45%
Total Debt$3.38M$2.83M$75.60M$75.77M2165.75%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.